DDInter1266 DDInter826
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glipizide
Naproxen {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Glipizide
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Naproxen {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glipizide
Naproxen {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Naproxen {u} (Compound) causes {v} (Side Effect) Muscle spasms
Muscle spasms {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Naproxen {u} (Compound) causes {v} (Side Effect) Haematochezia
Haematochezia {u} (Side Effect) is caused by {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Naproxen {u} (Compound) causes {v} (Side Effect) Stomach ache
Stomach ache {u} (Side Effect) is caused by {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glipizide (Compound)
Naproxen (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Glipizide (Compound)
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Naproxen (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Glipizide (Compound)
Naproxen (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Naproxen (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide
Naproxen (Compound) causes Haematochezia (Side Effect) and Haematochezia (Side Effect) is caused by Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Naproxen (Compound) causes Stomach ache (Side Effect) and Stomach ache (Side Effect) is caused by Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)